PWA
TEVA icon

Principia Wealth Advisory’s Teva Pharmaceuticals TEVA Stock Holding History

Principia Wealth Advisory’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.9K Buy
115
+19
+20% +$633 ﹤0.01% 419
2026
Q1 		$2.89K Buy
96
+17
+22% +$547 ﹤0.01% 423
2025
Q4 		$2.47K Sell
79
-1
-1% -$25 ﹤0.01% 402
2025
Q3 		$1.62K Buy
80
+58
+264% +$1.02K ﹤0.01% 485
2025
Q2 		$369 Buy
+22
New +$355 ﹤0.01% 802

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Principia Wealth Advisory's TEVA Position: Q2 2026 in Review

Principia Wealth Advisory increased its Teva Pharmaceuticals (TEVA) stake by 20% in Q2 2026, buying an estimated $633 and bringing the position to 115 shares worth $3.9K. The position accounts for ﹤0.01% of the portfolio, ranked #419.

Principia Wealth Advisory first reported a position in TEVA in Q2 2025 and has held it in 5 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Principia Wealth Advisory held 115 shares of Teva Pharmaceuticals worth $3.9K as of Q2 2026.
  • Principia Wealth Advisory bought 19 Teva Pharmaceuticals shares in Q2 2026, an estimated $633.
  • Teva Pharmaceuticals made up ﹤0.01% of Principia Wealth Advisory's portfolio in Q2 2026, its #419 holding.
  • Principia Wealth Advisory first reported a position in Teva Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Principia Wealth Advisory's 13F filing for Q2 2026, filed 26 Aug 2026.